Health & Fitness
Health and Fitness
Health and Fitness
Mon, January 26, 2009 Sequenom Names Allan T. Bombard, M.D., Chief Medical Officer
SAN DIEGO--([ BUSINESS WIRE ])--Sequenom, Inc. (NASDAQ: SQNM) today announced that it has named Allan T. Bombard, M.D., to the newly created position of Chief Medical Officer. Dr. Bombard will oversee Sequenom's clinical and medical affairs, including clinical strategy, operations and clinical advocacy.
"Allan has played an instrumental role in the development of our noninvasive prenatal diagnostic division, including serving as the principal investigator in a screening study to clinically assess the Company's noninvasive prenatal diagnostic technology for the detection of Down syndrome from a maternal blood sample," said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. "We are very pleased to have his leadership and experience on a full-time basis, and we welcome him aboard."
"I am delighted to join Sequenom and contribute to the development of this groundbreaking technology that will revolutionize prenatal screening," said Dr. Bombard. "Our efforts will lead to a dramatic reduction in the need for invasive procedures, improve detection rates over currently available screening models and help to alleviate the anxiety among pregnant women that results from invasive procedures. The potential to greatly impact prenatal care makes it very rewarding to be a part of the Sequenom leadership team."
Before joining Sequenom, Dr. Bombard was the Chief Executive Officer of Lenetix Medical Laboratory of Mineola, New York. Prior to joining Lenetix, he was Chief Medical Officer of Sharp Mary Birch Hospital in San Diego, the largest women's hospital in the western United States. Before joining Sharp Healthcare, he was Senior Vice President, Chair and Residency Program Director, Department of Obstetrics and Gynecology at Lutheran Medical Center, Brooklyn, New York. Dr. Bombard came to Lutheran Medical Center from Aetna, Inc., where he served as the Western U.S. Medical Director for Women's Health. Prior to Aetna, he served as Director, Reproductive Genetics, Department of Obstetrics and Gynecology & Women's Health at Montefiore Medical Center and the Albert Einstein College of Medicine in Bronx, New York, and he continues to hold a Clinical Professorship at Einstein.
Dr. Bombard received his B.A. degree from Colgate University, his Doctor of Medicine degree from the George Washington University School of Medicine and Health Sciences, and completed an M.B.A. at the University of San Diego. He completed a residency in obstetrics and gynecology at the Wilford Hall USAF Medical Center in San Antonio, and his fellowship in Clinical Genetics at Northwestern University in Chicago. Dr. Bombard is board certified in both Ob/Gyn and Clinical Genetics.
Dr. Bombard retired from the USAF Reserves in 2002 with the rank of Colonel, and served in Operation Desert Storm. He is a Founding Fellow of the American College of Medical Genetics, a Fellow of the American College of Obstetricians & Gynecologists, and a life member of the American College of Physician Executives. He has lectured extensively on a variety of women's health issues including genetic counseling, prenatal screening and diagnosis, the business of medicine, and BRCA screening. His articles have appeared in peer-reviewed medical journals such as the Lancet and the American Journal of Obstetrics & Gynecology.
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate the results of genomic science into solutions for noninvasive prenatal diagnostics, biomedical research, translational research and molecular medicine applications. The Company's proprietary MassARRAY® system is a high-performance (in speed, accuracy and cost efficiency) nucleic acid analysis platform that quantitatively and precisely measures genetic target material and variations. The Company has exclusively licensed intellectual property rights for the development and commercialization of noninvasive prenatal genetic tests for use with the MassARRAY system and other platforms. For more information on Sequenom, please visit the Company's Web site at [ www.sequenom.com ].
Sequenom® and MassARRAY® are trademarks of Sequenom, Inc.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding anticipated benefits or impact of Sequenom's efforts and its technology, and the potential to greatly impact prenatal care, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Sequenom's operating performance, demand for and market acceptance of Sequenom's products, services, and technologies, new technology and product development and commercialization particularly for new technologies such as Sequenom's noninvasive prenatal diagnostic technology, reliance upon the collaborative efforts of other parties, research and development progress, competition, intellectual property protection, government regulation, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in Sequenom's SEC filings, including Sequenom's Annual Report on Form 10-K for the year ended December 31, 2007 and other documents subsequently filed with or furnished to the SEC. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
